ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
AIM ImmunoTech Inc

AIM ImmunoTech Inc (HXB2)

0.246
0.008
(3.36%)
Closed January 07 3:00PM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.246
Bid
0.22
Ask
0.234
Volume
20
0.246 Day's Range 0.246
0.178 52 Week Range 0.60
Previous Close
0.238
Open
0.246
Last Trade
20
@
0.246
Last Trade Time
Average Volume (3m)
5,419
Financial Volume
-
VWAP
-

HXB2 Latest News

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue OCALA, Fla., Dec. 12, 2024 (GLOBE...

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Preliminary finding of stable disease in two...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.04824.24242424240.1980.2460.19820930.22938535DE
40.03214.9532710280.2140.2460.18136180.2048468DE
120.0062.50.240.2460.17854190.20730622DE
26-0.108-30.50847457630.3540.3540.17851230.24214582DE
52-0.194-44.09090909090.440.60.17840370.30286747DE
156-0.3189999-56.4601692850.56499990.610.17838700.3333906DE
260-0.3189999-56.4601692850.56499990.610.17838700.3333906DE

HXB2 - Frequently Asked Questions (FAQ)

What is the current AIM ImmunoTech share price?
The current share price of AIM ImmunoTech is 0.246 €
What is the 1 year trading range for AIM ImmunoTech share price?
AIM ImmunoTech has traded in the range of 0.178 € to 0.60 € during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
3SXOKEA AS
9.6754 €
(419.07%)
4.5k
N8TGenerative AI Solutions Corp
0.186 €
(95.79%)
29.55k
7KOCullinan Metals Corp
0.0216 €
(80.00%)
1.5k
7XSPSPI Energy Co Ltd
0.75 €
(79.43%)
21.53k
Y31Infinitii Ai Inc
0.08 €
(75.82%)
12.77M
BZZBank of Montreal
9.695 €
(-89.54%)
802
L7C2Windfall Geotek Inc
0.003 €
(-64.71%)
1.32k
WWRWoolworths Group Limited
9.6584 €
(-48.07%)
443
1UR1Bee Vectoring Technologies International Inc
0.003 €
(-45.45%)
373.86k
CNWCodon AG
0.007 €
(-36.36%)
50
Y31Infinitii Ai Inc
0.08 €
(75.82%)
12.77M
PF8European Lithium Limited
0.029 €
(8.21%)
5.51M
76M0Realbotix Corp
0.322 €
(-16.15%)
4.8M
D7GNel ASA
0.2668 €
(-0.78%)
4.4M
3CPXiaomi Corporation
4.2595 €
(-5.48%)
3.82M

Discussion

View Full Feed
extrinsic55 extrinsic55 22 seconds ago
SGBX ask .64 High$1.00InAfterHoursPushVolumeUP
SGBX
BottomBounce BottomBounce 29 seconds ago
Silver demand projections
The demand for silver from solar panel manufacturers is expected to increase by almost 170% by 2030. The research firm CRU suggests that the solar sector will demand 80–90 million ounces of silver per year between now and 2030 $NXT
NXT
scotty3371 scotty3371 40 seconds ago
Endless dilutions. Linda lost her audience about five years ago. At this time (within 3 month of mhra decision) there is zero interest in this stock; shareholders are warn out by decades waiting for management to do one thing right!
NWBO
extrinsic55 extrinsic55 40 seconds ago
SGBX ask .64 High$1.00InAfterHoursPushVolumeUP
SGBX
extrinsic55 extrinsic55 55 seconds ago
SGBX ask .64 High$1.00InAfterHoursPushVolumeUP
SGBX
BottomBounce BottomBounce 1 minute ago
Silver demand projections
The demand for silver from solar panel manufacturers is expected to increase by almost 170% by 2030. The research firm CRU suggests that the solar sector will demand 80–90 million ounces of silver per year between now and 2030 $ENPH
ENPH
crescentmotor crescentmotor 1 minute ago
we're getting spoiled when we complain about a 35-40 cents UP day

True dat! My AVXL position value has been ramping up bigly since December 20!
AVXL
SuperLogisticsMan SuperLogisticsMan 1 minute ago
Well, we had a very strong start and then selling hit. I believe $CYBL increased their share count to 5.993 billion and restricted went up to 716.4 million. So, we are still issuing restricted stock to key players.

But I also saw postings about a huge announcement coming. Perhaps
CYBL
somberfox somberfox 2 minutes ago
2029 for news.
CLNV
north40000 north40000 2 minutes ago
There was a NVDA 10 for 1 stock split later in 2024 that resulted in our present 7550 shares(with resultant entry of $0.43 in December 2009), now trading ~ $142 per share. Other than that, you are correct that current loss in Amarin share value in 2 portfolios is well covered by market value of each
CVS JNJ MSFT
Ribo Ribo 2 minutes ago
$IDVV, Reg D , Letter of Intent

https://mineral-rite.com/wp-content/uploads/2025/01/2025-01-07-REGULATION-D-OFFERING-ANNOUNCEMENT_vFNL-Series-D.pdf

https://mineral-rite.com/wp-content/uploads/2025/01/2025-01-07-SUPPLEMENTAL-INFORMATION-MATERIAL-EVENT_vFNL.pdf
IDVV
Vytis Vytis 2 minutes ago
They are targeting big business. Think front desk greeters, amusement park characters, brand ambassadors, companionship in nursing homes etc. These would be clients that would make larger/multiple purchases.

They also have proprietary AI and patented skin technology they could licen
XBOTF
Dobies Dobies 2 minutes ago
I hope this was the start of something good and not a fluke!
SPI
moondogaz moondogaz 2 minutes ago
SMH
HMBL
BottomBounce BottomBounce 2 minutes ago
https://www.youtube.com/shorts/CYUy2cqtZ1w $FSLR
FSLR
gfp927z gfp927z 2 minutes ago
Derf, >> LEN
UFPI
Implanting Implanting 3 minutes ago
You're right. I didn't catch it the first time I watched the video, but go to about 10:20 into the video and he talks about raising $60+ million from selling assets in the portfolio, then he says they've had to raise equity through dilution AND MAY HAVE TO DO MORE.

That didn't take v
FFMGF
barttt barttt 3 minutes ago
lol trip zeros on 9400 shares 
ASKH
BottomBounce BottomBounce 3 minutes ago
$PAAS https://www.youtube.com/shorts/CYUy2cqtZ1w
PAAS
lakers17 lakers17 3 minutes ago
Well at least you own many OTCs and cryptos unlike others especially on the cryptos. 2025 will be a huge crypto year not a big OTC year, in my opinion. I do not beleive in anything BCDS is doing or will actually pull off and am only here because of the NSA* connection. How much did you lose there
BCDS
firebag1 firebag1 3 minutes ago
SANA HUGE MOVE AFTER HOURS
SANA
Knowledge is King Knowledge is King 4 minutes ago
Thanks all on AYSI
BottomBounce BottomBounce 4 minutes ago
Bank of America, the price of silver is expected to reach $35 per ounce *$30 now, with their analysts predicting a bullish trend for silver price. #silver #silversqueeze $WPM
WPM
Gizzer211 Gizzer211 4 minutes ago
UMAV:  style="font-size: 1em"Nice close at .012, let's see the stair stepping continue tomorrow towards .015+  
UMAV
packerfan9 packerfan9 4 minutes ago
A blind man can see that. They have done this now since early 2021. Same thing all over again. The sales on last filing 167,000. Shares to create that issued. R/s and Billions. They get rich selling shares not CBD.
CBDL